Effects of hexahydrocurcumin in combination with 5-fuorouracil on dimethylhydrazine-induced colon cancer in rats

World Journal of Gastroenterology

Volumn 18, Issue 47, 2012, Pages 6951-6959

  Srimuangwong, Khanitta ^a   Tocharus, Chainarong ^b   Tocharus, Jiraporn ^b   Suksamrarn, Apichart ^c   Chintana, Pornphorm Yoysungnoen ^d  

^a NARESUAN UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c RAMKHAMHAENG UNIVERSITY   (Thailand)

^d THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Colon cancer; Combination treatment; Curcumin analog; Cyclooxygenase 2; Hexahydrocurcumin

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIMETHYLHYDRAZINE; FLUOROURACIL; HEXAHYDROCURCUMIN; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INFRARED SPECTROSCOPY; MALE; MASS SPECTROMETRY; MONOTHERAPY; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

EID: 84873896815     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i47.6951     Document Type: Article

References (34)

1. Hwang JT, Ha J, Park OJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005; 332: 433-440
2. Carnesecchi S, Bras-Gonçalves R, Bradaia A, Zeisel M, Gossé F, Poupon MF, Raul F. Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fuoro-uracil efficacy on human colon tumor xenografts. Cancer Lett 2004; 215: 53-59
3. Du B, Jiang L, Xia Q, Zhong L. Synergistic inhibitory effects of curcumin and 5-fuorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy 2006; 52: 23-28
4. Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol 2007; 105: 104-112
5. Hanif R, Qiao L, Shiff SJ, Rigas B. Curcumin, a natural plant phenolic food additive, inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997; 130: 576-584
6. Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, Reddy BS. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999; 59: 597-601
7. Lee KW, Kim JH, Lee HJ, Surh YJ. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal 2005; 7: 1612-1620
8. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, Ben-Yosef R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007; 25: 411-418
9. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 1996; 51: 21-28
10. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980; 16: 259-265
11. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-1876
12. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76: 1590-1611
13. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull 2007; 30: 74-78
14. Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 2003; 63: 5218-5223
15. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, Howells L, Plummer S, Jukes R, Williams M, Steward WP, Gescher A. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 2001; 61: 1058-1064
16. Srimuangwong K, Tocharus C, Yoysungnoen Chintana P, Suksamrarn A, Tocharus J. Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells. World J Gastroenterol 2012; 18: 2383-2389
17. Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem 2010; 45: 941-956
18. Bouzourene H, Chaubert P, Seelentag W, Bosman FT, Saraga E. Aberrant crypt foci in patients with neoplastic and non-neoplastic colonic disease. Hum Pathol 1999; 30: 66-71
19. McLellan EA, Bird RP. Aberrant crypts: potential preneoplastic lesions in the murine colon. Cancer Res 1988; 48: 6187-6192
20. Taché S, Ladam A, Corpet DE. Chemoprevention of aber- rant crypt foci in the colon of rats by dietary onion. Eur J Cancer 2007; 43: 454-458
21. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991; 51: 1564-1567
22. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995; 93: 55-71
23. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991; 22: 287-294
24. Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane- induced rat colon carcinogenesis. Carcinogenesis 2000; 21: 1319-1327
25. Harris RE. Cyclooxygenase-2 (cox-2) and the infammogenesis of cancer. Subcell Biochem 2007; 42: 93-126
26. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-1594
27. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by co- lon cancer cells. Cell 1998; 93: 705-716
28. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277: 27613-27621
29. Elder DJ, Halton DE, Playle LC, Paraskeva C. The MEK/ ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 2002; 99: 323-327
30. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002; 62: 6323-6328
31. Shpitz B, Giladi N, Sagiv E, LevAri S, Liberman E, Kazanov D, Arber N. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74: 140-144
32. Engelhardt G, Bögel R, Schnitzler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38
33. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28: 67-81
34. Fosslien E. Review: molecular pathology of cyclooxygen-ase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 2001; 31: 325-348